223 related articles for article (PubMed ID: 34722297)
1. Enhancer RNA SLIT2 Inhibits Bone Metastasis of Breast Cancer Through Regulating P38 MAPK/c-Fos Signaling Pathway.
Li P; Lin Z; Liu Q; Chen S; Gao X; Guo W; Gong F; Wei J; Lin H
Front Oncol; 2021; 11():743840. PubMed ID: 34722297
[TBL] [Abstract][Full Text] [Related]
2. Identification of the enhancer RNAs related to tumorgenesis of pituitary neuroendocrine tumors.
Wang L; Wei C; Wang Y; Huang N; Zhang T; Dai Y; Xue L; Lin S; Wu ZB
Front Endocrinol (Lausanne); 2023; 14():1149997. PubMed ID: 37534217
[TBL] [Abstract][Full Text] [Related]
3. Construction of Bone Metastasis-Specific Regulation Network Based on Prognostic Stemness-Related Signatures in Breast Invasive Carcinoma.
Huang R; Li Z; Zhang J; Zeng Z; Zhang J; Li M; Wang S; Xian S; Xue Y; Chen X; Li J; Cheng W; Wang B; Yan P; Yang D; Huang Z
Front Oncol; 2020; 10():613333. PubMed ID: 33585235
[TBL] [Abstract][Full Text] [Related]
4. Evaluate the immune-related eRNA models and signature score to predict the response to immunotherapy in thyroid carcinoma.
Wu P; Shi J; Wang Z; Sun W; Zhang H
Cancer Cell Int; 2022 Oct; 22(1):307. PubMed ID: 36217201
[TBL] [Abstract][Full Text] [Related]
5. Identification of Key eRNAs for Spinal Cord Injury by Integrated Multinomial Bioinformatics Analysis.
Huang R; Wang S; Zhu R; Xian S; Huang Z; Cheng L; Zhang J
Front Cell Dev Biol; 2021; 9():728242. PubMed ID: 34708039
[No Abstract] [Full Text] [Related]
6. Identification and validation of endocrine resistance-related and immune-related long non-coding RNA (lncRNA) signatures for predicting endocrinotherapy response and prognosis in breast cancer.
Yang M; Sun Y; Ji H; Zhang Q
Ann Transl Med; 2022 Dec; 10(24):1399. PubMed ID: 36660659
[TBL] [Abstract][Full Text] [Related]
7. Establishment of a N1-methyladenosine-related risk signature for breast carcinoma by bioinformatics analysis and experimental validation.
Li L; Yang W; Jia D; Zheng S; Gao Y; Wang G
Breast Cancer; 2023 Jul; 30(4):666-684. PubMed ID: 37178414
[TBL] [Abstract][Full Text] [Related]
8. Identification of Prognostic Alternative Splicing Signature in Breast Carcinoma.
Zhang D; Duan Y; Cun J; Yang Q
Front Genet; 2019; 10():278. PubMed ID: 30984247
[TBL] [Abstract][Full Text] [Related]
9. A seven-nuclear receptor-based prognostic signature in breast cancer.
Wu F; Chen W; Kang X; Jin L; Bai J; Zhang H; Zhang X
Clin Transl Oncol; 2021 Jul; 23(7):1292-1303. PubMed ID: 33210236
[TBL] [Abstract][Full Text] [Related]
10. Analysis of C-X-C motif chemokine receptors in breast cancer: potential value in immunotherapy and prognostic prediction.
Sun Y; Yang M; Zhang Q
Ann Transl Med; 2022 Dec; 10(24):1379. PubMed ID: 36660642
[TBL] [Abstract][Full Text] [Related]
11. Oncogenic signaling pathway-related long non-coding RNAs for predicting prognosis and immunotherapy response in breast cancer.
Li H; Liu H; Hao Q; Liu X; Yao Y; Cao M
Front Immunol; 2022; 13():891175. PubMed ID: 35990668
[TBL] [Abstract][Full Text] [Related]
12. Integrative Analysis of N6-Methyladenosine-Related Enhancer RNAs Identifies Distinct Prognosis and Tumor Immune Micro-Environment Patterns in Head and Neck Squamous Cell Carcinoma.
Cai H; Liang J; Jiang Y; Tan R; Hou C; Hou J
Cancers (Basel); 2022 Sep; 14(19):. PubMed ID: 36230580
[TBL] [Abstract][Full Text] [Related]
13. Identification and Validation of an Immune-Related eRNA Prognostic Signature for Hepatocellular Carcinoma.
Cai S; Hu X; Chen R; Zhang Y
Front Genet; 2021; 12():657051. PubMed ID: 34178028
[TBL] [Abstract][Full Text] [Related]
14. eRNAs Identify Immune Microenvironment Patterns and Provide a Novel Prognostic Tool in Acute Myeloid Leukemia.
Jiang Z; Long J; Deng K; Zheng Y; Chen M
Front Mol Biosci; 2022; 9():877117. PubMed ID: 35586193
[No Abstract] [Full Text] [Related]
15. The therapeutic effect and targets of
Yuan J; Lin M; Yang S; Yin H; Ouyang S; Xie H; Tang H; Ou X; Zeng Z
Heliyon; 2024 May; 10(10):e31137. PubMed ID: 38778969
[TBL] [Abstract][Full Text] [Related]
16. Identification of the prognostic value of ferroptosis-related gene signature in breast cancer patients.
Wang D; Wei G; Ma J; Cheng S; Jia L; Song X; Zhang M; Ju M; Wang L; Zhao L; Xin S
BMC Cancer; 2021 May; 21(1):645. PubMed ID: 34059009
[TBL] [Abstract][Full Text] [Related]
17. Multi-omics analysis revealing a senescence-relevant lncRNAs signature for the assessment of response to immunotherapy for breast cancer.
Yu Z; Zhu Y; Ji J
Medicine (Baltimore); 2023 Jul; 102(28):e34287. PubMed ID: 37443486
[TBL] [Abstract][Full Text] [Related]
18. Identification and Validation of Novel Metastasis-Related Immune Gene Signature in Breast Cancer.
Ma S; Hao R; Lu YW; Wang HP; Hu J; Qi YX
Breast Cancer (Dove Med Press); 2024; 16():199-219. PubMed ID: 38634039
[TBL] [Abstract][Full Text] [Related]
19. Identification and validation of HOXD3 and UNC5C as molecular signatures in keloid based on weighted gene co-expression network analysis.
Wang H; Zhou Z; Liu Y; Wang P; Chen L; Qi S; Xie J; Tang J
Genomics; 2022 Jul; 114(4):110403. PubMed ID: 35709926
[TBL] [Abstract][Full Text] [Related]
20. Repression of enhancer RNA PHLDA1 promotes tumorigenesis and progression of Ewing sarcoma
Huang R; Huang D; Wang S; Xian S; Liu Y; Jin M; Zhang X; Chen S; Yue X; Zhang W; Lu J; Liu H; Huang Z; Zhang H; Yin H
Front Genet; 2022; 13():952162. PubMed ID: 36092920
[No Abstract] [Full Text] [Related]
[Next] [New Search]
